Protein typing of circulating microvesicles allows real-time monitoring of glioblastoma therapy

H. Shao, J. Chung, L. Balaj, A. Charest, D. D. Bigner, B. S. Carter, F. H. Hochberg, X. O. Breakefield, R. Weissleder, and H. Lee. Protein typing of circulating microvesicles allows real-time monitoring of glioblastoma therapy. Nat Med, 18(12):1835–1840, Dec 2012. [PubMed Central:\href https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3518564PMC3518564] [DOI:\href https://dx.doi.org/10.1038/nm.299410.1038/nm.2994] [PubMed:\href https://www.ncbi.nlm.nih.gov/pubmed/2152756321527563].
[BibTeX▼]

@article{pmid23142818,
    Author = "Shao, H. and Chung, J. and Balaj, L. and Charest, A. and Bigner, D. D. and Carter, B. S. and Hochberg, F. H. and Breakefield, X. O. and Weissleder, R. and Lee, H.",
    Title = "{{P}rotein typing of circulating microvesicles allows real-time monitoring of glioblastoma therapy}",
    Journal = "Nat Med",
    Year = "2012",
    Volume = "18",
    Number = "12",
    Pages = "1835--1840",
    Month = "Dec",
    Abstract = "Glioblastomas shed large quantities of small, membrane-bound microvesicles into the circulation. Although these hold promise as potential biomarkers of therapeutic response, their identification and quantification remain challenging. Here, we describe a highly sensitive and rapid analytical technique for profiling circulating microvesicles directly from blood samples of patients with glioblastoma. Microvesicles, introduced onto a dedicated microfluidic chip, are labeled with target-specific magnetic nanoparticles and detected by a miniaturized nuclear magnetic resonance system. Compared with current methods, this integrated system has a much higher detection sensitivity and can differentiate glioblastoma multiforme (GBM) microvesicles from nontumor host cell-derived microvesicles. We also show that circulating GBM microvesicles can be used to analyze primary tumor mutations and as a predictive metric of treatment-induced changes. This platform could provide both an early indicator of drug efficacy and a potential molecular stratifier for human clinical trials.",
    Note = "[PubMed Central:\href{https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3518564}{PMC3518564}] [DOI:\href{https://dx.doi.org/10.1038/nm.2994}{10.1038/nm.2994}] [PubMed:\href{https://www.ncbi.nlm.nih.gov/pubmed/21527563}{21527563}]"
}

Abstract

Glioblastomas shed large quantities of small, membrane-bound microvesicles into the circulation. Although these hold promise as potential biomarkers of therapeutic response, their identification and quantification remain challenging. Here, we describe a highly sensitive and rapid analytical technique for profiling circulating microvesicles directly from blood samples of patients with glioblastoma. Microvesicles, introduced onto a dedicated microfluidic chip, are labeled with target-specific magnetic nanoparticles and detected by a miniaturized nuclear magnetic resonance system. Compared with current methods, this integrated system has a much higher detection sensitivity and can differentiate glioblastoma multiforme (GBM) microvesicles from nontumor host cell-derived microvesicles. We also show that circulating GBM microvesicles can be used to analyze primary tumor mutations and as a predictive metric of treatment-induced changes. This platform could provide both an early indicator of drug efficacy and a potential molecular stratifier for human clinical trials.